The gardner syndrome treatment market size has grown steadily in recent years. It will grow from $19.37 billion in 2024 to $20.19 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to advancements in medical research, government regulations, increasing prevalence of gardner syndrome, market competition, healthcare infrastructure.
The gardner syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $25.05 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to innovations in treatment, market trends, global economic factors, patient preferences, pricing and reimbursement policies. Major trends in the forecast period include precision medicine advancements, immunotherapy breakthroughs, gene therapy innovation, diagnostic technologies, and collaborative research initiatives.
The anticipated increase in colon cancer cases is projected to drive the expansion of the market for Gardner syndrome treatment in the future. Colon cancer, originating in the large intestine, necessitates Gardner syndrome treatment to prevent cancer by removing polyps during a colonoscopy and employing chemotherapy. Notably, the American Society of Clinical Oncology (ASCO) reported in May 2022 that there were over 1.5 million colon cancer survivors in the USA, with expectations for this number to rise. The 5-year survival rate also witnessed a 65 percent increase, with 51,030 adults diagnosed with colon cancer in 2022, further fueling the growth of the Gardner syndrome treatment market.
The growing trend of medical tourism is expected to significantly drive the growth of the Gardner syndrome treatment market. Medical tourism refers to individuals traveling to other countries for medical care, healthcare services, or surgical procedures. Countries that cater to medical tourists offer advanced technologies and treatment options for Gardner syndrome. For example, in August 2024, data from the Private Healthcare Information Network (PHIN), a UK-based government-mandated organization, revealed that non-UK patient admissions increased to 10,640 in 2023, with the most notable rise (144%) occurring between 2021 and 2022 when travel restrictions were lifted after the COVID-19 pandemic. This increase in medical tourism is a key factor propelling the Gardner syndrome treatment market.
A noteworthy trend in gaining traction within the Gardner syndrome treatment market is product innovation. Leading companies in the market are focused on developing innovative solutions to strengthen their market position. For example, in December 2022, Genentech Inc., a US-based biotechnology corporation, introduced an innovative medicine named 'Lunsumio' (mosunetuzumab-axgb), approved by the U.S. Food and Drug Administration (FDA). This medicine, designed to treat adults with follicular lymphoma and rare diseases, stands out due to its intensive monitoring capabilities and its ability to provide T cells for enhanced defense against infections while effectively destroying cancer cells in the human body.
Major companies in the gardner syndrome treatment market are launching new products. In November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, unveiled Fruzaqla (fruquintinib), the first drug approved by the FDA for the treatment of metastatic colorectal cancer (mCRC) in adults. Fruzaqla targets all three subtypes of the vascular endothelial growth factor (VEGF) receptor kinases, making it a crucial treatment option, especially for patients with Gardner syndrome who are at a higher risk of developing colorectal cancer.
In February 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company, completed the acquisition of Amunix Pharmaceuticals Inc. for an undisclosed amount. This strategic move by Sanofi S.A. underscores its commitment to investing in promising research and discovery platforms, gaining access to Amunix's technologies, and accelerating the development of innovative medicines for oncology patients. Amunix Pharmaceuticals Inc., a US-based immuno-oncology and biopharmaceutical company, focuses on developing transformative therapies for oncology patients and manufacturing pharmaceutical products.
Major companies operating in the gardner syndrome treatment market include Biochem Pharmaceuticals Industries Limited, Zydus Lifesciences Limited, Vernalis (R&D) Limited, Sun Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Mayne Pharma Group Limited, Akorn Operating Company LLC, Johnson & Johnson Private Limited, Medimetriks Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Iris Pharma, Merck & Co. Inc., AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd.
North America was the largest region in the gardner syndrome treatment market in 2024. The regions covered in the gardner syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gardner syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Gardner syndrome is a form of familial adenomatous polyposis (FAP) characterized by the development of multiple colon polyps and various tumors, both cancerous and noncancerous. The treatment for Gardner syndrome involves closely monitoring the polyps through lower gastrointestinal tract endoscopy, effectively restricting the growth of colon polyps.
The primary cancer types addressed in the treatment of Gardner syndrome include dilated cardiomyopathy, skeletal myopathy, neutropenia, and others. Dilated cardiomyopathy, a heart muscle disease that causes the chambers (ventricles) to thin and stretch, resulting in enlargement, is one of the key concerns. Therapeutic approaches encompass nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, applied in hospitals, specialty clinics, and various other settings.
The gardner syndrome treatment market research report is one of a series of new reports that provides gardner syndrome treatment market statistics, including gardner syndrome treatment industry global market size, regional shares, competitors with gardner syndrome treatment market share, detailed gardner syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the gardner syndrome treatment industry. This gardner syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gardner syndrome treatment market includes revenues earned by entities by providing services such as screenings of colonoscopy, sigmoidoscopy, and EGD (esophagogastroduodenoscopy) services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The gardner syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $25.05 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to innovations in treatment, market trends, global economic factors, patient preferences, pricing and reimbursement policies. Major trends in the forecast period include precision medicine advancements, immunotherapy breakthroughs, gene therapy innovation, diagnostic technologies, and collaborative research initiatives.
The anticipated increase in colon cancer cases is projected to drive the expansion of the market for Gardner syndrome treatment in the future. Colon cancer, originating in the large intestine, necessitates Gardner syndrome treatment to prevent cancer by removing polyps during a colonoscopy and employing chemotherapy. Notably, the American Society of Clinical Oncology (ASCO) reported in May 2022 that there were over 1.5 million colon cancer survivors in the USA, with expectations for this number to rise. The 5-year survival rate also witnessed a 65 percent increase, with 51,030 adults diagnosed with colon cancer in 2022, further fueling the growth of the Gardner syndrome treatment market.
The growing trend of medical tourism is expected to significantly drive the growth of the Gardner syndrome treatment market. Medical tourism refers to individuals traveling to other countries for medical care, healthcare services, or surgical procedures. Countries that cater to medical tourists offer advanced technologies and treatment options for Gardner syndrome. For example, in August 2024, data from the Private Healthcare Information Network (PHIN), a UK-based government-mandated organization, revealed that non-UK patient admissions increased to 10,640 in 2023, with the most notable rise (144%) occurring between 2021 and 2022 when travel restrictions were lifted after the COVID-19 pandemic. This increase in medical tourism is a key factor propelling the Gardner syndrome treatment market.
A noteworthy trend in gaining traction within the Gardner syndrome treatment market is product innovation. Leading companies in the market are focused on developing innovative solutions to strengthen their market position. For example, in December 2022, Genentech Inc., a US-based biotechnology corporation, introduced an innovative medicine named 'Lunsumio' (mosunetuzumab-axgb), approved by the U.S. Food and Drug Administration (FDA). This medicine, designed to treat adults with follicular lymphoma and rare diseases, stands out due to its intensive monitoring capabilities and its ability to provide T cells for enhanced defense against infections while effectively destroying cancer cells in the human body.
Major companies in the gardner syndrome treatment market are launching new products. In November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, unveiled Fruzaqla (fruquintinib), the first drug approved by the FDA for the treatment of metastatic colorectal cancer (mCRC) in adults. Fruzaqla targets all three subtypes of the vascular endothelial growth factor (VEGF) receptor kinases, making it a crucial treatment option, especially for patients with Gardner syndrome who are at a higher risk of developing colorectal cancer.
In February 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company, completed the acquisition of Amunix Pharmaceuticals Inc. for an undisclosed amount. This strategic move by Sanofi S.A. underscores its commitment to investing in promising research and discovery platforms, gaining access to Amunix's technologies, and accelerating the development of innovative medicines for oncology patients. Amunix Pharmaceuticals Inc., a US-based immuno-oncology and biopharmaceutical company, focuses on developing transformative therapies for oncology patients and manufacturing pharmaceutical products.
Major companies operating in the gardner syndrome treatment market include Biochem Pharmaceuticals Industries Limited, Zydus Lifesciences Limited, Vernalis (R&D) Limited, Sun Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Mayne Pharma Group Limited, Akorn Operating Company LLC, Johnson & Johnson Private Limited, Medimetriks Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Iris Pharma, Merck & Co. Inc., AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd.
North America was the largest region in the gardner syndrome treatment market in 2024. The regions covered in the gardner syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gardner syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Gardner syndrome is a form of familial adenomatous polyposis (FAP) characterized by the development of multiple colon polyps and various tumors, both cancerous and noncancerous. The treatment for Gardner syndrome involves closely monitoring the polyps through lower gastrointestinal tract endoscopy, effectively restricting the growth of colon polyps.
The primary cancer types addressed in the treatment of Gardner syndrome include dilated cardiomyopathy, skeletal myopathy, neutropenia, and others. Dilated cardiomyopathy, a heart muscle disease that causes the chambers (ventricles) to thin and stretch, resulting in enlargement, is one of the key concerns. Therapeutic approaches encompass nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, applied in hospitals, specialty clinics, and various other settings.
The gardner syndrome treatment market research report is one of a series of new reports that provides gardner syndrome treatment market statistics, including gardner syndrome treatment industry global market size, regional shares, competitors with gardner syndrome treatment market share, detailed gardner syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the gardner syndrome treatment industry. This gardner syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gardner syndrome treatment market includes revenues earned by entities by providing services such as screenings of colonoscopy, sigmoidoscopy, and EGD (esophagogastroduodenoscopy) services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Gardner Syndrome Treatment Market Characteristics3. Gardner Syndrome Treatment Market Trends and Strategies4. Gardner Syndrome Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Gardner Syndrome Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Gardner Syndrome Treatment Market34. Recent Developments in the Gardner Syndrome Treatment Market
5. Global Gardner Syndrome Treatment Growth Analysis and Strategic Analysis Framework
6. Gardner Syndrome Treatment Market Segmentation
7. Gardner Syndrome Treatment Market Regional and Country Analysis
8. Asia-Pacific Gardner Syndrome Treatment Market
9. China Gardner Syndrome Treatment Market
10. India Gardner Syndrome Treatment Market
11. Japan Gardner Syndrome Treatment Market
12. Australia Gardner Syndrome Treatment Market
13. Indonesia Gardner Syndrome Treatment Market
14. South Korea Gardner Syndrome Treatment Market
15. Western Europe Gardner Syndrome Treatment Market
16. UK Gardner Syndrome Treatment Market
17. Germany Gardner Syndrome Treatment Market
18. France Gardner Syndrome Treatment Market
19. Italy Gardner Syndrome Treatment Market
20. Spain Gardner Syndrome Treatment Market
21. Eastern Europe Gardner Syndrome Treatment Market
22. Russia Gardner Syndrome Treatment Market
23. North America Gardner Syndrome Treatment Market
24. USA Gardner Syndrome Treatment Market
25. Canada Gardner Syndrome Treatment Market
26. South America Gardner Syndrome Treatment Market
27. Brazil Gardner Syndrome Treatment Market
28. Middle East Gardner Syndrome Treatment Market
29. Africa Gardner Syndrome Treatment Market
30. Gardner Syndrome Treatment Market Competitive Landscape and Company Profiles
31. Gardner Syndrome Treatment Market Other Major and Innovative Companies
35. Gardner Syndrome Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Gardner Syndrome Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on gardner syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gardner syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gardner syndrome treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Cancer Type: Dilated Cardiomyopathy; Skeletal Myopathy; Neutropenia; Other Cancer Types2) by Therapeutics Type: NonSteroidal Anti-Inflammatory Drugs (NSAIDs); COX-2 Inhibitor
3) by Application: Hospitals; Specialty Clinics; Other Applications
Subsegments:
1) by Dilated Cardiomyopathy: Pharmacological Treatments; Surgical Interventions2) by Skeletal Myopathy: Physical Therapy; Supportive Care
3) by Neutropenia: Growth Factors; Antimicrobial Therapy
4) by Other Cancer Types: Colorectal Cancer; Osteomas; Other Associated Tumors
Key Companies Mentioned: Biochem Pharmaceuticals Industries Limited; Zydus Lifesciences Limited; Vernalis (R&D) Limited; Sun Pharmaceutical Industries Ltd.; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Gardner Syndrome Treatment market report include:- Biochem Pharmaceuticals Industries Limited
- Zydus Lifesciences Limited
- Vernalis (R&D) Limited
- Sun Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- Mayne Pharma Group Limited
- Akorn Operating Company LLC
- Johnson & Johnson Private Limited
- Medimetriks Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Iris Pharma
- Merck & Co. Inc.
- AstraZeneca plc
- Bristol Myers Squibb Company
- Eli Lilly and Company
- AbbVie Inc.
- Amgen Inc.
- Gilead Sciences Inc.
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cadila Healthcare Ltd.
- Torrent Pharmaceuticals Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 20.19 Billion |
| Forecasted Market Value ( USD | $ 25.05 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
